Literature DB >> 9661609

Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility.

B Imani1, M J Eijkemans, E R te Velde, J D Habbema, B C Fauser.   

Abstract

The diagnostic criteria used to identify patients suffering from polycystic ovary syndrome remain controversial. The present prospective longitudinal follow-up study was designed to identify whether certain criteria assessed during standardized initial screening could predict the response to ovulation induction with clomiphene citrate (CC) in 201 patients presenting with oligomenorrhea or amenorrhea and infertility. Serum FSH levels were within the normal range (1-10 IU/L), and all patients underwent spontaneous or progestin-induced withdrawal bleeding. Initial CC doses were 50 mg daily for 5 days starting on cycle day 3. In the case of an absent response, doses were increased to 100 and 150 mg daily in subsequent cycles. First ovulation with CC was used as the end point. After a complete follow-up (in the case of a nonresponse, at least 3 treatment cycles with daily CC doses up to 150 mg), 156 patients (78%) ovulated. The free androgen index (FAI = testosterone/sex hormone-binding globulin ratio), body mass index (BMI), cycle history (oligomenorrhea vs. amenorrhea), serum androgen (testosterone and/or androstenedione) levels, and mean ovarian volume assessed by transvaginal sonography were all significantly different (P < 0.01) in responders from those in nonresponders. FAI was chosen to be the best predictor in univariate analysis. The area under the receiver operating characteristics curve in a multivariate prediction model including FAI, BMI, cycle history, and mean ovarian volume was 0.82. Patients whose ovaries are less likely to respond to stimulation by FSH due to CC treatment can be predicted on the basis of initial screening characteristics, such as FAI, BMI, cycle history (oligomenorrhea or amenorrhea), and mean ovarian volume. These observations may add to ongoing discussion regarding etiological factors involved in ovarian dysfunction in these patients and classification of normogonadotropic anovulatory infertile women.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9661609     DOI: 10.1210/jcem.83.7.4919

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  35 in total

1.  Improved responsiveness of PCOS patients to clomiphene after CYP17a inhibitor.

Authors:  H Ali Hassan; D El-Gezeiry; T M Nafaa; I Baghdady
Journal:  J Assist Reprod Genet       Date:  2001-11       Impact factor: 3.412

2.  Anovulation and ovulation induction.

Authors:  I Katsikis; M Kita; A Karkanaki; N Prapas; D Panidis
Journal:  Hippokratia       Date:  2006-07       Impact factor: 0.471

3.  Clomiphene citrate co-treatment with low dose urinary FSH versus urinary FSH for clomiphene resistant PCOS: randomized controlled trial.

Authors:  Mohamad E Ghanem; Laila A Elboghdady; Mohamad Hassan; Adel S Helal; Ahmed Gibreel; Maha Houssen; Mohamed E Shaker; Ibrahiem Bahlol; Yaser Mesbah
Journal:  J Assist Reprod Genet       Date:  2013-09-07       Impact factor: 3.412

Review 4.  Infertility in polycystic ovary syndrome: focus on low-dose gonadotropin treatment.

Authors:  Anwen Gorry; Davinia M White; Stephen Franks
Journal:  Endocrine       Date:  2006-08       Impact factor: 3.633

Review 5.  Pulsatile gonadotrophin releasing hormone for ovulation induction in subfertility associated with polycystic ovary syndrome.

Authors:  N Bayram; M van Wely; F van der Veen
Journal:  Cochrane Database Syst Rev       Date:  2004

6.  Prestimulation parameters predicting live birth in anovulatory WHO Group II patients undergoing ovulation induction with gonadotrophins.

Authors:  A Nyboe Andersen; A H Balen; P Platteau; G Pettersson; J-C Arce
Journal:  Hum Reprod       Date:  2010-06-03       Impact factor: 6.918

Review 7.  Recommendations for Premature Ovarian Insufficiency Surveillance for Female Survivors of Childhood, Adolescent, and Young Adult Cancer: A Report From the International Late Effects of Childhood Cancer Guideline Harmonization Group in Collaboration With the PanCareSurFup Consortium.

Authors:  Wendy van Dorp; Renée L Mulder; Leontien C M Kremer; Melissa M Hudson; Marry M van den Heuvel-Eibrink; Marleen H van den Berg; Jennifer M Levine; Eline van Dulmen-den Broeder; Natascia di Iorgi; Assunta Albanese; Saro H Armenian; Smita Bhatia; Louis S Constine; Andreas Corrias; Rebecca Deans; Uta Dirksen; Clarisa R Gracia; Lars Hjorth; Leah Kroon; Cornelis B Lambalk; Wendy Landier; Gill Levitt; Alison Leiper; Lillian Meacham; Alesandro Mussa; Sebastian J Neggers; Kevin C Oeffinger; Alberto Revelli; Hanneke M van Santen; Roderick Skinner; Andrew Toogood; William H Wallace; Riccardo Haupt
Journal:  J Clin Oncol       Date:  2016-07-25       Impact factor: 44.544

8.  Using an electrocautery strategy or recombinant follicle stimulating hormone to induce ovulation in polycystic ovary syndrome: randomised controlled trial.

Authors:  Neriman Bayram; Madelon van Wely; Eugenie M Kaaijk; Patrick M M Bossuyt; Fulco van der Veen
Journal:  BMJ       Date:  2004-01-24

9.  Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene.

Authors:  Richard S Legro; Huiman X Barnhart; William D Schlaff; Bruce R Carr; Michael P Diamond; Sandra A Carson; Michael P Steinkampf; Christos Coutifaris; Peter G McGovern; Nicholas A Cataldo; Gabriella G Gosman; John E Nestler; Linda C Giudice; Kathryn G Ewens; Richard S Spielman; Phyllis C Leppert; Evan R Myers
Journal:  J Clin Endocrinol Metab       Date:  2007-11-13       Impact factor: 5.958

10.  LH suppression following different low doses of the GnRH antagonist ganirelix in polycystic ovary syndrome.

Authors:  F P Hohmann; J S E Laven; A G M G J Mulders; J J L Oberyé; B M J L Mannaerts; F H de Jong; B C J M Fauser
Journal:  J Endocrinol Invest       Date:  2005-12       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.